Therapeutic Strategy Details
| Strategy ID: | S02 |
| Strategy: | Enhance lipid metabolism |
| Other Terms: | triglyceride-lowering; lipid tolerance; lipid metabolism |
| Related Targets: | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor |
| Related Drugs: | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; |
| Mechanism: | Fueled by lipo-apoptosis, hepatic steatosis leads to systemic metabolic disarray that adversely affects multiple organs, placing abnormal lipid metabolism associated with NAFLD in close relation to many of the current life-style-related diseases. |
| Reference (PMIDs): | 15333967; 29936596 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D013 | Aramchol | Chemical drug | DB11860 | SCD-1 | Enhance lipid metabolism | Under clinical trials | Details |
| D018 | Aspirin | Chemical drug | DB00945 | AKR1C1 inhibitor; PCNA downregulator | Enhance lipid metabolism | Under clinical trials | Details |
| D020 | Atorvastatin | Chemical drug | DB01076 | DPP4 inhibitor; AHR agonist; HDAC2 inhibitor; NR1I3 ligand | Enhance lipid metabolism | Under clinical trials | Details |
| D030 | Bergamot | Biological drug | DB14335 | -- | Enhance lipid metabolism | Under clinical trials | Details |
| D040 | BIO89-100 | Biological drug | -- | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism | Under clinical trials | Details |
| D046 | Pegbelfermin | Biological drug | DB15365 | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism; Anti-fibrosis | Under clinical trials | Details |
| D062 | Carnitine complex | Supplement | DB00583 | SLC22A4; SLC22A5; CRAT; MPO | -- | Under clinical trials | Details |
| D075 | Choline | Supplement | DB00122 | PLD2 product of; PLD1 product of | -- | Under clinical trials | Details |
| D078 | Cilofexor | Chemical drug | DB15168 | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| D117 | EDP-305 | Chemical drug | -- | FXR agonist | Enhance lipid metabolism | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0088 | DB00227 | approved; investigational | small molecule | Lovastatin | Therapeutic strategy associated | Details |
| R0164 | DB00481 | approved; investigational | small molecule | Raloxifene | Therapeutic strategy associated | Details |
| R0227 | DB00641 | approved | small molecule | Simvastatin | Therapeutic strategy associated | Details |
| R1067 | DB06641 | investigational | small molecule | Perifosine | Therapeutic strategy associated | Details |
| R1096 | DB06778 | approved | small molecule | Cupric sulfate | Therapeutic strategy associated | Details |
| R1312 | DB09462 | approved; investigational | small molecule | Glycerin | Target associated | Details |
| R1338 | DB11117 | approved; investigational | small molecule | Undecylenic acid | Therapeutic strategy associated | Details |
| R1427 | DB12007 | experimental | small molecule | Isoflavone | Therapeutic strategy associated | Details |
| R1547 | DB14960 | approved | biotech | Somatrogon | Therapeutic strategy associated | Details |
| R1559 | DB15354 | approved; investigational | biotech | Evinacumab | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00007 | 35256601 | Cell Death Discov | LncRNA MEG3 up-regulates SIRT6 by ubiquitinating EZH2 and alleviates nonalcoholic fatty liver disease. | Details |
| A00022 | 35251469 | Oxid Med Cell Longev | Farnesoid X Receptor Deficiency Induces Hepatic Lipid and Glucose Metabolism Disorder via Regulation of Pyruvate Dehydrogenase Kinase 4. | Details |
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | Details |
| A00044 | 35246007 | Bioengineered | Quantitative proteomics analysis based on tandem mass tag labeling coupled with labeling coupled with liquid chromatography-tandem mass spectrometry discovers the effect of silibinin on non-alcoholic fatty liver disease in mice. | Details |
| A00055 | 35240510 | Biochem Biophys Res Commun | Inulin activates FXR-FGF15 signaling and further increases bile acids excretion in non-alcoholic fatty liver disease mice. | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | Details |
| A00092 | 35222799 | Oxid Med Cell Longev | 4-Octyl Itaconate Prevents Free Fatty Acid-Induced Lipid Metabolism Disorder through Activating Nrf2-AMPK Signaling Pathway in Hepatocytes. | Details |
| A00094 | 35222044 | Front Pharmacol | Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. | Details |
| A00096 | 35220997 | Discov Med | Farnesoid X Receptor as a Promising Therapeutic Target for Nonalcoholic Fatty Liver Disease (NAFLD) and the Current Development of Its Agonists. | Details |
| A00106 | 35217953 | Environ Sci Pollut Res Int | Environmental exposure to low-dose perfluorohexanesulfonate promotes obesity and non-alcoholic fatty liver disease in mice fed a high-fat diet. | Details |
| A00121 | 35213002 | Methods Mol Biol | Analysis of the Sphingolipidome in NAFLD. | Details |
| A00135 | 35212985 | Methods Mol Biol | Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH). | Details |
| A00136 | 35212984 | Methods Mol Biol | Measurement of Hepatic Lipids. | Details |
| A00174 | 35198905 | iScience | Deletion of RNF186 expression suppresses diet-induced hepatic steatosis by regulating insulin activity. | Details |
| A00177 | 35197460 | Nat Commun | Kindlin-2 haploinsufficiency protects against fatty liver by targeting Foxo1 in mice. | Details |
| A00183 | 35195377 | Minerva Endocrinol (Torino) | Inflammation is associated with impairment of oxidative status, carbohydrate and lipid metabolism in type 2 diabetes complicated by non-alcoholic fatty liver disease. | Details |
| A00188 | 35192934 | Mol Ther | Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma. | Details |
| A00205 | 35187676 | J Food Biochem | Chitosan oligosaccharide attenuates hepatic steatosis in HepG2 cells via the activation of AMP-activated protein kinase. | Details |
| A00209 | 35185113 | J Pediatr Gastroenterol Nutr | Comparison of the Lipidomic Signature of Fatty Liver in Children and Adults: A Cross-Sectional Study. | Details |
| A00214 | 35182330 | Mol Cell Biochem | Menin regulates lipid deposition in mouse hepatocytes via interacting with transcription factor FoxO1. | Details |